Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Unknown 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 11CNS 10Gastrointestinal 8Breast 5Head & Neck 4Sarcoma 3Genitourinary 3Other solid neoplasm 2Endocrine 2Tumor-Agnostic 1Other neoplasm 1NET 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Relapsed Pediatric Solid Tumor 1

Interventions

Cisplatin 60Carboplatin 55Cyclophosphamide 47Pemetrexed 45Irinotecan 33pembrolizumab 32Paclitaxel 29Etoposide 29Gemcitabine 28Nivolumab 24Bevacizumab 24Interviews as Topic 23Vincristine 22Capecitabine 22Topotecan 20Filgrastim 20Early Intervention, Educational 20fludarabine 19Oxaliplatin 19Docetaxel 19Specimen Handling 18Drug Therapy 18Temozolomide 17Sorafenib 17Leucovorin 17Everolimus 17Educational Status 17Radiotherapy 16Methods 16Fluorouracil 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × vandetanib × Other solid neoplasm × Clear all
NCT02638428 2020-03-19

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Samsung Medical Center

Phase 2 Unknown
90 enrolled
Other solid neoplasm

Relapsed Pediatric Solid Tumor

NCT00601614 2014-03-10

Vandetanib and Temozolomide in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery

Mayo Clinic

Phase 1 Withdrawn
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡